Mutant KRAS is correlated with poor prognosis in CRC and resistance to Epidermal Growth Factor Receptor (EGFR) antibodies, and immune checkpoint blocker such as anti-PD1 [4]. The gene discussed is EGFR; the disease is colorectal carcinoma.